Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636347 · ClinicalTrials.gov registry record · Phase 2
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
A Phase 2 study, sponsored by Mereo BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT03636347 is a Phase 2 study that has completed, run by Mereo BioPharma. The registered enrollment target is 99 participants.
The verdict
NCT03636347, a Phase 2 study, has completed, sponsored by Mereo BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare variant phenotype/genotype alpha-1 anti-trypsin deficient lung disease. Change in a number of different blood and sputum biomarkers related to lung damage, inflammation and elastase activity will be measured over a 12 week period. The effect on lung function and respiratory symptoms will also be measured.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Alvelestat oral tablet - dose 1
- DRUG Alvelestat oral tablet - dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03636347
The ClinicalTrials.gov registry entry for NCT03636347 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mereo BioPharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Oral Tablet is the first listed.
NCT03636347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03636347 about?
NCT03636347 is a clinical study titled "A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.". The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare variant phenotype/genotype alpha-1 anti-trypsin deficient lung disease. Change in a number of different blood and sputum bio...
What is the current status of trial NCT03636347?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2018-10-29. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT03636347?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Alvelestat oral tablet - dose 1 (DRUG), Alvelestat oral tablet - dose 2 (DRUG).
Who is sponsoring clinical trial NCT03636347?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.